Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis

72Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: A poor biological response to clopidogrel is associated with an increased risk of major cardiovascular ischemic events (MACE). Paraoxonase 1 (PON1) enzyme activity is modulated by the PON1-Q192R variant (rs662) and was recently suggested to be strongly involved in clopidogrel bioactivation, but the influence of the PON1-Q192R variant on the risk of MACE in clopidogrel-treated patients is controversial. Objectives: To determine whether the PON1-Q192R variant influences clopidogrel biological responsiveness and the risk of MACE in patients treated with clopidogrel. Methods: Systematic review and meta-analysis of studies of the association between the PON1-Q192R polymorphism and the biological response to clopidogrel and/or the risk of MACE during clopidogrel administration. Results: Seventeen studies were included. In the 12 studies of the biological response to clopidogrel (n=5302 patients), there was no significant difference between 192QQ and 192QR+192RR subjects, whatever the laboratory method used (global mean standardized difference=0.10 [-0.06; 0.25], P=0.22). Eleven studies assessed the risk of MACE, four using a case-control design (n=2739 patients) and seven a prospective design (n=5353 patients). Overall, MACE occurred in 19% of patients in case-control studies and in 6% of patients in prospective cohort studies, with no significant difference between 192QQ and 192QR+192RR patients (OR=1.28 [0.97; 1.68], P=0.08). Similar results were obtained when study design was taken into account. Heterogeneity was mainly driven by one publication. Conclusions: This meta-analysis suggests that the PON1-Q192R polymorphism has no major impact on the risk of MACE and does not alter the biological response to clopidogrel in clopidogrel-treated patients. © 2012 International Society on Thrombosis and Haemostasis.

References Powered by Scopus

Bias in meta-analysis detected by a simple, graphical test

43016Citations
N/AReaders
Get full text

Meta-analysis in clinical trials

32910Citations
N/AReaders
Get full text

Meta-analysis of observational studies in epidemiology: A proposal for reporting

17845Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update

805Citations
N/AReaders
Get full text

Vascular oxidative stress, nitric oxide and atherosclerosis

554Citations
N/AReaders
Get full text

Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

162Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Reny, J. L., Combescure, C., Daali, Y., Fontana, P., Aradi, D., Delaney, J., … Trenk, D. (2012). Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 10(7), 1242–1251. https://doi.org/10.1111/j.1538-7836.2012.04756.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

58%

Professor / Associate Prof. 6

23%

Researcher 3

12%

Lecturer / Post doc 2

8%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 9

43%

Medicine and Dentistry 7

33%

Pharmacology, Toxicology and Pharmaceut... 3

14%

Biochemistry, Genetics and Molecular Bi... 2

10%

Save time finding and organizing research with Mendeley

Sign up for free